# OnCo record paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016" ;
  schema:name "Inherited DNA-repair gene mutations in men with metastatic prostate cancer"@en ;
  schema:alternateName "Pritchard 2016"@en, "germline DNA repair metastatic prostate 11.8 percent"@en ;
  schema:description "Nearly one man in eight with prostate cancer that has spread carries an inherited fault in a DNA repair gene, most often BRCA2. Family history and age at diagnosis did not predict who: the only way to find them is to test everybody."@en ;
  schema:url <https://onco.cc/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/nejmoa1603144>, <https://pubmed.ncbi.nlm.nih.gov/27433846/>, <https://doi.org/10.1056/NEJMoa1603144> ;
  onco:tag "prostate-evidence" ;
  schema:sameAs <https://doi.org/10.1056/nejmoa1603144> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Pritchard CC, Mateo J, Walsh MF, et al." ;
  onco:related <https://onco.cc/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/>, <https://onco.cc/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/>, <https://onco.cc/key-papers/paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997/>, <https://onco.cc/ideas/idea-prev-reflex-germline-testing/>, <https://onco.cc/roadmaps/prostate-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mhspc/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/prevention/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/atm/>, <https://onco.cc/targets/chek2/>, <https://onco.cc/targets/palb2/>, <https://onco.cc/targets/rad51d/> ;
  onco:institutions <https://onco.cc/institutions/fred-hutch/>, <https://onco.cc/institutions/royal-marsden/> ;
  onco:pathways <https://onco.cc/pathways/homologous-recombination-repair/>, <https://onco.cc/pathways/ddr/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/terms/lynch-syndrome/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-hereditary-risk/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-care-fragmentation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .